Lungpacer Medical (Canada)

Lungpacer Medical is a medical device company focused on neurostimulation technologies for critical care, best known for developing the AeroPace Neurostimulation System (also referred to as the Lungpacer Diaphragm Pacing System). The company describes itself as a leader in neurostimulation designed to transform critical care, with more than 15 years of innovation in ventilator weaning. Its core technology is a temporary transvenous diaphragm neurostimulation system that stimulates the phrenic nerves controlling the diaphragm through an intuitive catheter-based approach intended to fit into existing critical care workflows. The clinical proposition of AeroPace is to restore independent breathing and enhance ventilator weaning. According to the company, the system outperformed standard-of-care in a randomized clinical trial, with reported outcomes including 43% faster weaning from mechanical ventilation over 30 days, 3.2 fewer days on mechanical ventilation in the ICU, 47% lower risk of reintubation or reconnection to ventilation, and 50% lower risk of tracheostomy. Additional reported benefits include greater diaphragm strength and breathing efficiency, a lower risk of mortality, and a low risk of infection with zero CLABSI in the trial population. The RESCUE-3 randomized controlled trial was performed in a diverse, difficult-to-wean population with prolonged mechanical ventilation and marked diaphragm atrophy. Lungpacer Medical is associated with Vancouver, Canada, and has also built a US team and operations. The company's key milestones include first human use of the Lungpacer Diaphragm Pacing System in 2015, the start of the RESCUE 1 clinical study in 2016, FDA Breakthrough Device designation and the start of RESCUE 2 in 2017, the start of US team and operations in 2018, the start of RESCUE 3 in 2019, FDA Emergency Use Authorization in 2020 to support the COVID-19 pandemic response, and US Premarket Approval for the AeroPace System in 2024. In 2025 the Wall Street Journal published an article about Lungpacer. The company is led by President and CEO Doug Evans, a medical device executive with 30 years of industry experience and a serial innovator of first-of-their-kind products. Lungpacer has pursued reimbursement pathways for its therapy, including NTAP and new Category III CPT codes for AeroPace diaphragm neurostimulation therapy, and it has announced health economic analyses demonstrating clinical and cost benefits in mechanically ventilated patients. In 2026, Lungpacer Medical was nominated for a Prix Galien USA Award for Best Medical Technology, recognizing the AeroPace System as the first FDA-approved diaphragm neurostimulation therapy to help critically ill patients breathe on their own again.

Lungpacer Medical is a medical device company focused on neurostimulation technologies for critical care, with more than 15 years of innovation in ventilator weaning. The company is associated with Vancouver, Canada, and has also established a US team and operations. The company's key milestones trace a decade-long clinical and regulatory journey. In 2015, the first human use of the Lungpacer Diaphragm Pacing System took place. In 2016, the RESCUE 1 clinical study began. In 2017, the FDA designated Lungpacer as a "Breakthrough Device," and the RESCUE 2 clinical study began. In 2018, the US team and operations started. In 2019, the RESCUE 3 clinical study began. In 2020, the FDA granted Emergency Use Authorization to support the COVID-19 pandemic response. In 2024, the AeroPace System received US Premarket Approval. In 2025, the Wall Street Journal published an article about Lungpacer. The company's flagship technology, the AeroPace Neurostimulation System, is a temporary transvenous diaphragm neurostimulation system that stimulates the phrenic nerves controlling the diaphragm using an intuitive catheter-based approach that fits seamlessly into existing critical care workflows. Its clinical proposition is to restore independent breathing and enhance ventilator weaning. According to the company, the AeroPace System outperformed standard-of-care in a randomized clinical trial, with reported outcomes including 43% faster weaning from mechanical ventilation over 30 days, 3.2 fewer days on mechanical ventilation in the ICU, 47% lower risk of reintubation or reconnection to ventilation, and 50% lower risk of tracheostomy. Additional reported benefits include 74% greater diaphragm strength (MIP), 96% greater breathing efficiency (RSBI), 32% lower risk of mortality, and a low risk of infection with zero CLABSI. The RESCUE-3 randomized controlled trial was performed in a diverse, difficult-to-wean population with prolonged mechanical ventilation and marked diaphragm atrophy. The company reports that 97% of patients in the RESCUE-3 trial would recommend AeroPace, and that its evidence base includes 103 scientific abstracts/presentations, 31 peer-reviewed publications, over 400 patients studied, and 2+ randomized clinical trials. Lungpacer Medical is led by President and CEO Doug Evans, a medical device executive with 30 years of industry, public, and private company experience. He is a serial innovator of first-of-their-kind products and has over 200 issued patents covering dozens of devices used by over 15 million patients worldwide, generating greater than $4 billion in end-user sales. He serves as Chairman for TELA Bio (NASDAQ: TELA) and Board Member for WhiteSwell Medical. Previously he served as Operating Director, Secretary, and Board Member of Intact Vascular (acquired by Royal Philips for $360M in 2020); as advisor to Essential Medical (acquired by Teleflex in 2018); and as Chief Operating Officer and Board Member of Kensey Nash. The company has pursued reimbursement pathways for its therapy, including NTAP and new Category III CPT codes for AeroPace diaphragm neurostimulation therapy, and it has announced health economic analyses demonstrating clinical and cost benefits in mechanically ventilated patients. In 2026, Lungpacer Medical was nominated for a Prix Galien USA Award for Best Medical Technology, recognizing the AeroPace System as the first FDA-approved diaphragm neurostimulation therapy to help critically ill patients breathe on their own again.

• 2026

  Lungpacer Medical nominated for 2026 Prix Galien USA Award for Best Medical Technology.

• 2025

  Wall Street Journal publishes article about Lungpacer.

• 2024

  AeroPace System receives US Premarket Approval.

• 2020

  FDA Approval of Emergency Use Authorization to support COVID-19 Pandemic response.

• 2019

  RESCUE 3 Clinical Study begins.

• 2018

  US team and operations start.

• 2017

  FDA designates Lungpacer as a "Breakthrough Device." RESCUE 2 Clinical Study begins.

• 2016

  RESCUE 1 Clinical Study begins.

• 2015

  First human use of Lungpacer Diaphragm Pacing System.

Leader in neurostimulation technologies designed to transform critical care and improve ventilator weaning outcomes.

• AeroPace Neurostimulation System

  A temporary transvenous diaphragm neurostimulation system that stimulates the phrenic nerves controlling the diaphragm using an intuitive catheter-based approach that fits seamlessly into existing critical care workflows. It restores independent breathing and enhances ventilator weaning.

• Lungpacer Diaphragm Pacing System

  The company's diaphragm pacing system, first used in humans in 2015.

1. 1Lungpacer® System | Diaphragm Pacing Technologylungpacer.com
2. 2About Lungpacer | Medical Device Innovationlungpacer.com
3. 3Clinical Evidence | Lungpacer® Systemlungpacer.com
4. 4Lungpacer Medical (Canada) - Wikidatawikidata.org